Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
University of Utah
Would you use CTS5 to help you decide whether to offer prolonged adjuvant ET to HR+ breast cancer?
Answer from: Medical Oncologist at Community Practice
I would
Sign in or Register to read more
5507
Related Questions
How do the findings from the INAVO120 trial influence your decision-making process for selecting subsequent lines of therapy in patients who have relapsed after adjuvant CDK4/6 inhibition?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?
What are your top takeaways in Breast Cancer from ESMO 2024?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
How would you approach treatment for a postmenopausal patient who was treated more than 5 years ago with AC-T for TNBC, and who now presents with ipsilateral, locally advanced, node-positive TNBC, but has severe residual neuropathy from prior taxane exposure?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
What are your top takeaways in Medical Oncology from SABCS 2024?